Your session is about to expire
← Back to Search
plamotamab for Non-Hodgkin's Lymphoma
Study Summary
This trial will study if a combination of drugs is safe and effective in treating people with a certain type of blood cancer that has come back or does not respond to other treatments.
- Non-Hodgkin's Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the federal regulatory status of plamotamab?
"Taking into account the Phase 2 classification, which indicates limited evidence regarding safety but no proof of efficacy, plamotamab is rated at a two on our safety scale."
Is there an ongoing call for participants right now?
"Affirmative, the information presented on clinicaltrials.gov demonstrates that this research is actively recruiting participants. This trial was posted to their website on June 30th 2022 and has been updated as recently as May 2nd 2021; requiring a total of 240 patients from one site for enrolment in the study."
How many individuals can participate in this clinical trial?
"Affirmative. Records available through clinicaltrials.gov demonstrate that this research is currently in the process of recruiting participants, with the initial post on June 30th 2022 and last edited May 2nd 2022. Ultimately, 240 individuals are needed to be recruited from a single site."
Share this study with friends
Copy Link
Messenger